Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.93 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.93 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.60 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.60 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KDM5C | P41229 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.41 |
| ▸ | KDM6B | O15054 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Ketoglutaric Acid SCHEMBL30208560 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL7400 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL30029036 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL932116 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL17127347 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL3776640 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL29783374 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL3184813 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL1242830 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL20877597 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636311-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | GALLEON LABS LLC (US) | 2026-05-26 | — | — | US | claimed |
| US-20250099498-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2025-03-27 | — | — | US | claimed |
| US-12121536-B2 | Strontium based compositions and formulations for pain, pruritus, and inflammation | GALLEON LABS LLC (US) | 2024-10-22 | — | — | US | claimed |
| US-20240041919-A1 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION | GALLEON LABS LLC | 2024-02-08 | — | — | US | claimed |
| US-11801261-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | GALLEON LABS LLC (US) | 2023-10-31 | — | — | US | claimed |
| CN-115414265-A | Composition and face cream with effects of color correction, skin tendering and moisturizing and preparation method thereof | 中国科学院过程工程研究所 | 2022-12-02 | — | — | CN | claimed |
| US-20220323485-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | PIKE, JOSEPH D. | 2022-10-13 | — | — | US | claimed |
| EP-2827847-B1 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION | GALLEON LABS LLC (US) | 2022-09-14 | — | — | EP | claimed |
| EP-3284462-B1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2022-08-03 | — | — | EP | claimed |
| US-20220054535-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | STRONTIUM NEUROGENICS INC (US) | 2022-02-24 | — | — | US | claimed |
| EP-2266585-A2 | Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions | Osteologix A/S (DK) | 2010-12-29 | — | — | EP | claimed |
| EP-1732575-B1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | OSTEOLOGIX AS (DK) | 2010-12-29 | — | — | EP | claimed |
| EP-1768748-B1 | COMPOSITIONS COMPRISING STRONTIUM AND VITAMIN D AND USES THEREOF | STRONTIN APS (DK) | 2009-09-23 | — | — | EP | claimed |
| US-20080260714-A1 | Nutrient mixture comprising fibrin, thrombin and a strontium-containing compound for use as therapeutic in bone healing or bone growth | BAXTER INTERNATIONAL INC. (US) | 2008-10-23 | — | — | US | claimed |
| US-20080167513-A1 | Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions | OSTEOLOGLX A/S (DK) | 2008-07-10 | — | — | US | claimed |
| EP-1732575-A1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | Osteologix A/S (DK) | 2006-12-20 | — | — | EP | claimed |
| US-20060122274-A1 | Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions | OSTEOLOGIX A/S (DK) | 2006-06-08 | — | — | US | claimed |
| WO-2005082385-A1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2005-09-09 | — | — | WO | claimed |
| EP-1534305-A2 | TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS | Osteologix A/S (DK) | 2005-06-01 | — | — | EP | claimed |
| WO-2004098619-A2 | TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636311-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | SUCNR1, TRPV1, TRPV2 | EGLN1 770/4885OR51E2 3212/4885MAPK1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.